drugset / Trial / NCT07224776
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Phase 1
Not yet recruiting
20 enrolled
Brigham and Women's Hospital
Travere Therapeutics, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors
Timeline
- Start
- 2026-06-10
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sparsentan | Small molecule | 400 mg | — |